LL-37

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Active autoimmune disease: LL-37 is a potent immunological alarm signal that activates multiple innate immune pathways simultaneously (TLR-4, FPRL1, mast cell degranulation, neutrophil chemotaxis); in subjects with active autoimmune conditions, this immune activation can trigger severe flares by amplifying the already-dysregulated immune response against self-tissue.
• Systemic lupus erythematosus (SLE): LL-37 has been specifically implicated in SLE pathogenesis: endogenous LL-37 forms complexes with self-DNA that activate TLR-9 on plasmacytoid dendritic cells, driving the type-I interferon signature that characterizes SLE; exogenous LL-37 administration in SLE subjects could dramatically worsen disease activity.
• Psoriasis (active, severe): LL-37 is a primary initiator of psoriatic inflammation; it forms complexes with self-DNA in psoriatic skin lesions that activate the pDC/TLR-7/9 pathway driving IL-23/IL-17 pathological cascade; LL-37 administration in psoriatic subjects may severely worsen plaques.
• Rheumatoid arthritis (active disease): cathelicidin-mediated immune activation in inflamed joints could precipitate acute synovitis flares.
• Organ transplant recipients: immune activation from LL-37 in immunosuppressed transplant recipients may provoke rejection episodes.
• Concurrent anticoagulant therapy: LL-37 activates mast cells and platelets; theoretical interaction with anticoagulation warrants monitoring.
• Known hypersensitivity to LL-37, cathelicidin-derived peptides, or formulation excipients.
• Subjects with a very high established pathogen burden without clinical supervision: the Herxheimer reaction at LL-37 initiation in subjects with severe Lyme, MRSA, or fungal burdens can be medically dangerous; clinical oversight and KPV availability for Herxheimer management is strongly advisable.
• Pregnancy: immune activation and cytokine release from LL-37 carry risk in pregnancy; not established as safe.
• Breastfeeding: no safety data.
• Active inflammatory bowel disease (Crohn's, UC) in severe flare: gut epithelial LL-37 dysregulation is already implicated in IBD pathogenesis; systemic exogenous LL-37 during active flare could worsen mucosal inflammation.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Jarisch-Herxheimer Reaction (JHR): the primary, defining, and most clinically significant adverse effect of LL-37 when used for chronic infection; characterized by sudden onset of fever (often 38-40°C), severe chills, intense fatigue, diaphoresis, myalgia, arthralgia, and headache occurring within hours of the first few doses; caused by mass simultaneous pathogen killing releasing endotoxins and microbial antigens faster than the immune system can clear them; severity is proportional to pathogen burden and is the reason for mandatory slow dose escalation.
• Intense injection site welts and induration: a consistent and dose-dependent adverse effect; LL-37's cationic amphipathic structure interacts with subcutaneous tissue and activates local mast cells, producing significant local inflammatory welts that can be painful, warm, and raised; more pronounced than virtually any other peptide in this database; site rotation and starting at 50mcg are the primary management strategies.
• Severe joint pain (arthralgia): part of the Herxheimer reaction cascade; may be extreme in Lyme disease subjects as spirochete die-off in joint tissue releases inflammatory mediators.
• Profound fatigue: the systemic inflammatory response from Herxheimer reactions consumes significant metabolic resources; profound fatigue lasting 24-72 hours per episode is expected, particularly in early titration.
• Fever: Herxheimer reaction fever can reach 39-40°C and be alarming; it is a sign the LL-37 is working but should be monitored; subjects must be able to distinguish Herxheimer fever from infection-worsening fever.
• Chills and rigors: accompanies Herxheimer fever; can be intense; warm blankets, hydration, and rest are the management.
• Headache: common during Herxheimer reactions; related to systemic cytokine release (TNF-α, IL-6, IL-1β).
• Autoimmune flare triggering: in subjects with undiagnosed or quiescent autoimmune conditions; LL-37's TLR-9 activation and DNA-complex formation can unmask or worsen autoimmune pathology.
• Nausea and gastrointestinal disturbance: less common; part of the systemic inflammatory response during Herxheimer events.
• Pro-angiogenic activity: LL-37 stimulates VEGFR2-mediated angiogenesis; in the context of active malignancy this is a theoretical oncological concern; in wound healing contexts it is a therapeutic benefit.
• Potential mast cell activation syndrome (MCAS) exacerbation: subjects with underlying MCAS may experience severe reactions even at low doses due to LL-37's direct mast cell degranulation activity.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
• PubMed search: LL-37